Report Highlights

U.S. Drug Infusion Systems: Market Overview

The United States is the largest single national market for drug infusion systems, accounting for roughly 40 percent of global revenue and reaching USD 6.2 billion in 2024. Demand concentrates in acute hospital care, where large volume pumps, syringe pumps and smart-pump drug libraries are standard equipment. Unlike most global markets, purchasing is consolidated through group purchasing organizations such as Vizient and Premier, which negotiate multi-year agreements bundling pumps, sets and software. This structure lowers unit prices for incumbents but raises switching costs for new entrants.

Structurally, the market is shifting from inpatient wards toward ambulatory infusion centers and patients' homes. Disposables such as administration sets represent roughly half of annual spend, creating recurring revenue that differs from the capital-driven hospital equipment model common elsewhere. The Medicare Part B home infusion therapy benefit, created under the SUPPORT for Patients and Communities Act, has expanded reimbursement for non-hospital delivery. Fragmented distribution across specialty pharmacies and home infusion providers therefore creates an entry point distinct from hospital capital sales.

Growth Drivers in U.S. Infusion Systems

Demand is anchored by demographics. Nearly 58 million Americans are aged 65 and older, and this cohort accounts for most chronic infusion therapies, including immunoglobulin, oncology regimens and parenteral nutrition. Biologic growth compounds this effect, since Medicare Part B covers many monoclonal antibodies administered by infusion in outpatient settings. Hospital systems are expanding infusion-capable outpatient sites to capture this volume, sustaining steady pump and set procurement across the forecast period. Oncology infusion volumes continued to rise through 2024 as immunotherapy regimens lengthened.

Policy is the second driver. The CMS Acute Hospital Care at Home waiver lets qualifying hospitals treat acute patients in their homes, requiring home infusion pumps and sets for IV therapy. Medicare's home infusion therapy benefit reimburses professional services for patients on home IV medication, shifting economics toward ambulatory delivery. Finally, Joint Commission medication management standards and FDA-recommended smart pump drug libraries push hospitals to replace legacy pumps on seven-to-ten-year cycles, generating recurring refresh demand.

Market Restraints and Entry Barriers in the U.S.

FDA premarket requirements form the first barrier. Infusion pumps are Class II devices under 21 CFR 880.5725 and typically require 510(k) clearance, while combination drug-device products face PMA or BLA review. Clearance timelines often run six to twelve months, and the Quality Management System Regulation, effective February 2, 2026, aligns manufacturing audits with ISO 13485. Legacy recalls, including earlier BD Alaris software and pump module actions, heighten scrutiny on new entrants' software and alarm design.

Pricing and incumbency form the second barrier. GPO contracts lock in multi-year pump-and-set bundles with Baxter, BD and ICU Medical, leaving new entrants to win on clinical niches or price below bundled discounts. Section 301 tariffs on Chinese-origin components and the 2025 Section 232 investigation into medical devices add cost pressure for lower-priced imports. Medicare DMEPOS competitive bidding further compresses margins on ambulatory pumps, requiring entrants to model reimbursement cuts before committing capital.

Market Opportunities in U.S. Infusion Systems

Home infusion offers the nearest entry window. An estimated USD 1.1 billion of annual pump and set spend sits with home infusion pharmacies and specialty providers, including Option Care Health, which operates one of the largest networks in the country. Home pumps require simpler interfaces, lower-cost mechanics and cloud connectivity to clinicians, favoring focused entrants over diversified incumbents. Providers prioritize nursing-time savings, so vendors offering remote monitoring capture pricing premiums.

Ambulatory surgical centers and physician-owned infusion suites represent an estimated USD 900 million addressable segment for compact syringe and volumetric pumps through 2032. These sites buy outside hospital GPO cycles, allowing direct contracting with faster procurement decisions. Subcutaneous and on-body delivery of biologics adds a second window, as wearable injectors replace some short IV administrations. Entrants should target infusion suites first, then home providers, before hospital capital cycles reopen.

Market at a Glance

Leading Market Participants

• Becton, Dickinson and Company
• Baxter International
• ICU Medical
• Fresenius Kabi
• B. Braun Medical
• Moog Inc.
• Medtronic
• Terumo Medical Corporation
• InfuSystem Holdings
• Insulet Corporation

Regulatory and Policy Environment for U.S. Infusion Systems

The FDA regulates infusion systems under the Federal Food, Drug, and Cosmetic Act, with pumps classified under 21 CFR Part 880 and drug library expectations shaped by its 2010 Infusion Pump Improvement Initiative. The 510(k) program carries a 90-day FDA review goal, while the Quality Management System Regulation requires ISO 13485-aligned controls from February 2026. The Joint Commission's medication management standards require hospitals to manage high-alert infusion risks, shaping purchasing specifications. Manufacturers must also register and list devices under FDA establishment rules.

Reimbursement is administered by CMS. Ambulatory infusion pumps are covered under Medicare Part B durable medical equipment benefits under HCPCS code E0781, and suppliers bidding under the DMEPOS competitive bidding program face fixed reimbursement. The SUPPORT for Patients and Communities Act of 2018 created the Part B home infusion therapy services benefit, effective 2021. The Acute Hospital Care at Home waiver is the principal federal channel for hospital-level home care. No direct capital subsidies exist for manufacturers, so commercial viability depends on reimbursement design.

Long-Term Outlook for U.S. Infusion Systems

By 2032, the U.S. drug infusion systems market is projected to reach USD 9.9 billion, growing at a 6.0 percent CAGR from the 2025 base year. Hospitals will remain the largest buyer by value, but their share will decline as home and ambulatory settings capture a growing portion of volumes. Consolidation among pump makers will continue, with the top five suppliers holding most hospital placements under GPO contracts. Expect fleet-based service models to become standard in hospital procurement by the end of the decade.

Subcutaneous biologics and connected wearables will reshape device design, reducing reliance on large volume pumps for some chronic therapies. Software interoperability, cybersecurity expectations under FDA premarket guidance, and data-sharing requirements will raise the bar for new entrants. Manufacturers that combine dual-qualified sets, cloud-enabled pumps and service contracts will capture the strongest share gains through 2032. Companies that clear home and ambulatory niches by 2027 will hold positions when hospital capital cycles reopen.